LRFN5 and OLFM4 in Methamphetamine-Induced Psychosis
Recruiting
Observational Study
Methamphetamine Use Disorder
Methamphetamine-induced Psychosis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 49
- Sex
- Male
- Study type
- Observational
- Participants needed
- 120 (estimated)
- Sponsor
- Elazığ Mental Health and Diseases Hospital · Government
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This cross-sectional observational case-control study aimed to examined serum levels of leucine-rich repeat and fibronectin type III domain-containing protein 5 (LRFN5) and olfactomedin-4 (OLFM4) levels in methamphetamine use disorder (MUD), methamphetamine-induced psychotic disorder (MP), and healthy control (HC) groups. The study also aimed to assessed systemic inflammation using the Aggregate I…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
1. For Methamphetamine Use Disorder (MUD) Group:
\*Inclusion Criteria:
* Diagnosis of MUD according to DSM-5-TR
* Medication-free for at least one month prior to admission
* Age ≥ 18 years and \<65 years
* Provided informed consent
For Methamphetamine Use Disorder (MUD) Group:
…
Contacts